In addition to the significant reductions in C-reactive protein and NT-proBNP reported in the STEP-HFpEF trial with semaglutide use in patients with obesity and HFpEF, a subsequent substudy demonstrated further favorable effects. This evidence concerns the gene CRP and obesity disorder.